Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19742612 | 1.00 | KMT2A (0.43) | KMT2AMEN1L3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL19754005 | 0.86 | SMN1; SMN2 (0.40) | KMT2AMEN1L3MBTL1ALDH1A1TDP1 | |
| SCHEMBL30279892 | 0.86 | SMN1; SMN2 (0.40) | KMT2AMEN1L3MBTL1ALDH1A1TDP1 | |
| SCHEMBL29356476 | 0.86 | SMN1; SMN2 (0.40) | KMT2AMEN1L3MBTL1ALDH1A1TDP1 | |
| SCHEMBL19742785 | 0.86 | SMN1; SMN2 (0.40) | KMT2AMEN1L3MBTL1ALDH1A1TDP1 | |
| SCHEMBL30279891 | 0.84 | L3MBTL1 (0.47) | KMT2AMEN1L3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL19742516 | 0.84 | L3MBTL1 (0.47) | KMT2AMEN1L3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL19742520 | 0.83 | KMT2A (0.40) | KMT2AMEN1L3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL19742706 | 0.83 | KMT2A (0.40) | KMT2AMEN1L3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL30279954 | 0.83 | KMT2A (0.40) | KMT2AMEN1L3MBTL1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3474855-B1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS INC (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3474855-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | Polaris Pharmaceuticals, Inc. (US) | 2019-05-01 | — | — | EP | disclosed |
| US-10227344-B2 | CK2 inhibitors, compositions and methods thereof | POLARIS PHARMACEUTICALS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20170369489-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS | 2017-12-28 | — | — | US | disclosed |
| WO-2017223432-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS (US) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369489-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | CSNK1A1, CSNK2A1, CSNK2A3 | KMT2A 772/4885MEN1 2862/4885L3MBTL1 3627/4885 |
| US-10227344-B2 | CK2 inhibitors, compositions and methods thereof | CSNK1A1, CSNK2A1, CSNK2A3 | KMT2A 772/4885MEN1 2862/4885L3MBTL1 3627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.